Approved: Sorafenib and Lenvatinib for the Treatment of Progressive, RAI-­Refractory DTC


Related Videos (117)

In this first of two videos on the refractory thyroid cancer, Marcia Brose, MD, discusses the approved multi­kinase inhibitors sorafenib and lenvatinib for progressive, RAI­-refractory differentiated thyroid cancer. Dr. Brose played a key role in the approval of sorafenib for thyroid cancer in 2013, and is widely considered a leading expert in the treatment of refractory thyroid cancer.

View the 2016 update on this topic here


Penn PhysicianLink®

Penn PhysicianLink® is an exclusive program that helps all referring physicians connect with Penn Medicine. This comprehensive package of support services expedites and facilitates direct physician communication for patient consults, referrals and transfers.

Learn more about Penn PhysicianLink®